Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) Price Target at $40.56

Pharvaris N.V. (NASDAQ:PHVS) has been given a consensus recommendation of “Moderate Buy” by the twelve analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $40.5556.

PHVS has been the subject of several research analyst reports. Leerink Partners set a $38.00 price target on shares of Pharvaris in a research note on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. Morgan Stanley boosted their target price on Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research note on Wednesday, December 3rd.

Pharvaris Stock Performance

Shares of PHVS opened at $26.25 on Friday. The firm has a market cap of $1.37 billion, a PE ratio of -8.18 and a beta of -2.80. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.80. The business’s 50 day moving average price is $24.56 and its two-hundred day moving average price is $22.65.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.08. Research analysts predict that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Trading of Pharvaris

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in Pharvaris during the second quarter worth $57,000. JPMorgan Chase & Co. increased its position in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Pharvaris during the third quarter worth about $75,000. Public Employees Retirement System of Ohio raised its holdings in shares of Pharvaris by 39.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock worth $156,000 after acquiring an additional 1,769 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after acquiring an additional 1,695 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.